Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Hypoxia 1Carcinoma, Hepatocellular 1

Interventions

lutetium Lu 177 dotatate 31Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7Capecitabine 7X-Rays 6Etoposide 6surufatinib 5olaparib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tirapazamine × Endocrine × 1 year × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡